MAPT and Alzheimer disease: Whether APOE by itself is druggable is debatable; however, it is tempting to suggest that targeting CNS APOE specifically early in the disease process could alter the pathologic trajectory of AD either directly by altering CNS pathologies like Aβ and tau and perhaps indirectly by influencing related sequelae, such as inflammation, metabolic impairment and vascular dysfunction.